Compare Abbott Laboratories (ABT) vs EPR Properties (EPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs EPR Properties — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while EPR Properties trades at $59.55 (market cap $4.58B). The key difference: Abbott Laboratories is far larger — about 36.4× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| ABT | EPR | |
|---|---|---|
Market Cap | $166.94B | $4.58B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $61.21 |
52-Week Low | $82.57 | $48.71 |
Enterprise Value | $193.69B | $7.64B |
Dividend Yield | 2.63% | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EPR Properties trades at $59.21, up 0.19% today, with a bullish technical signal supported by moving averages. The REIT shows strong profitability with a 39.93% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.26 versus $0.76 expected. Recent news highlights a $315 million Six Flags acquisition and inclusion on J.P. Morgan's July Focus List (247 Wallst, 2026-07-07).
Outlook remains positive with a consensus price target of $63.00, offering 6.4% upside. Key risks include reliance on experiential assets like theaters amid economic sensitivity, while the 6.2% dividend yield provides income support. Earnings on July 29, 2026, will be critical for validating growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
